In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pelikan Technologies Inc.

www.pelikantechnologies.com

Latest From Pelikan Technologies Inc.

Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q4 2007

Highlights from the Q4 2007 review of medical device and in vitro diagnostics/research dealmaking: there was a boost in medical device acquisitions--with patient monitoring in particular, which accounted for about half the total of this period--capping off an impressive year in medtech M&A activity. Of note in the in vitro diagnostics/research space was glucose monitoring, which brought in 60% of the total GM segment's $160 million in financing for the entire year.
BioPharmaceutical Medical Device

Deals Update (01/2008)

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Medical Device

Pelikan Swoops in on the Big Four

Following the strategy of those icons of success in the diabetes industry, Medisense and Therasense, Pelikan Technologies is executing well on its plan to develop a glucose monitoring platform that offers convience and freedom from pain, to reduce the current hurdles that prevent patients with diabetes from testing as much as they should. (Part of a group of articles that includes: "Where are They Now? Checking in on Three Glucose Monitoring Companies," "A Decade of Development of SMSI: Will it Yield Improved Accuracy in CGM?" and "GlucoLight: Making Non-Invasive Glucose Monitoring Real."
Medical Device Platform Technologies

Where are They Now? Checking in on Three Glucose-Monitoring Start-Ups

Laying out a strategy is one thing; executing it is another. That's why, from time to time, START-UP revisits companies it has written about in the past to find out what went according to plan, and what didn't. As we revisit the field of glucose monitoring--a field with a high attrition rate, we'll see if we can draw out some lessons, both from the successes and from the failures, for those starting out today. (Introduction to three separate articles in the December 2007 issue: "Pelikan Technologies Swoops in on the Big Four"; "A Decade of Development for SMSI: Will It Yield Improved Accuracy in CGM?" and "GlucoLight Makes Non-invasive Glucose Monitoring Real.")
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Glucose Testing
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pelikan Technologies Inc.
  • Senior Management
  • Dirk Boecker, MD, PhD, Pres. & CEO
    Patrick Nugent, CFO
  • Contact Info
  • Pelikan Technologies Inc.
    Phone: (650) 842-1000
    1072 East Meadow Cir.
    Palo Alto, CA 94303
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register